Research News and Research

RSS

Poll: Health care 'damage' to Democrats 'has been done'

Politico: "Democrats will face nearly the same political environment this fall whether or not they pass health care reform legislation, according to a new poll out Tuesday." The poll, by Public Policy Polling, found that "Republicans currently have a generic ballot advantage of 43 percent to 40 percent in races for Congress. ... 'At this point, it looks like the political damage for Democrats on health care has been done,' PPP President Dean Debnam said. "The poll, conducted Jan. 29 - 31, has a margin of error of plus or minus 4.1 percentage points" (Barr, 2/2).

3 Feb 2010

States consider their own health reform ideas

"Supporters of a bill that seeks to bar lifetime and annual payment caps on health insurance plans in Maine say they expect a large crowd at a legislative committee's hearing on the proposal." The same topic has been considered by the U.S. Congress as part of Democrats health overhaul (2/3).

3 Feb 2010

Major study of perfusion imaging under way to assess value of alternative diagnostic methods

Cardiologists and heart imaging specialists at 15 medical centers in eight countries, and led by researchers at Johns Hopkins, have enrolled the first dozen patients in a year-long investigation to learn whether the subtle squeezing of blood flow through the inner layers of the heart is better than traditional SPECT nuclear imaging tests and other diagnostic radiology procedures for accurately tracking the earliest signs of coronary artery clogs.

3 Feb 2010

Questionable health insurance plans cause concern

Officials worry that people with no insurance will be drawn in by questionable health insurance plans. ABC News reports: The "[h]ealth care overhaul is stalled, resulting in a proliferation of plans that don't fully protect people, officials said. Watchdogs worry about two kinds of plans in particular."

3 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

New York Times examines WHO process for getting H1N1 vaccines to countries in need

The New York Times examines the WHO's role as a "clearinghouse" for getting the H1N1 (swine flu) vaccine to lower income nations. Though H1N1 has died down in North America and many wealthier nations "are trying to get rid of their [vaccine] surpluses," the virus continues to circulate in regions of North Africa, Central Asia and Eastern Europe, according to the newspaper.

3 Feb 2010

Lobbying, ads slow down on health reform

"Drugmakers, business organizations and other interest groups in the health care battle have dialed down expensive lobbying campaigns as they assess how last month's stunning Republican capture of a Senate seat from Massachusetts has altered Washington's political landscape...," The Associated Press reports.

3 Feb 2010

Obama urges Senate Dems not to give up on health legislation

The Washington Post: President Obama attended an issues conference today with the Senate Democratic Caucus and "answered questions from senators, some of them facing uphill reelection battles."

3 Feb 2010

Study shows Cymbalta reduces chronic low back pain

In a new study, 60 mg of Cymbalta® (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.

3 Feb 2010

Lawmakers sound off on President's budget and health costs

While White House Budget Director Peter Orszag testified on Capitol Hill about President Obama's fiscal 2011 budget, some members expressed concern about health costs, McClatchy reports.

3 Feb 2010

House Dems' next step in health reform: Repeal of insurance antitrust exemption

Lawmakers "hoping to revive President Barack Obama's stalled health care overhaul have started writing a compromise bill, but it's unclear when the legislation will be ready for votes, a top House Democrat said Tuesday," The Associated Press reports. "The measure would change the massive Senate-approved health bill to what bargainers from the White House, Senate and House agreed to last month, Rep. Charles Rangel, D-N.Y., said in a brief interview.

3 Feb 2010

FDA approves Labopharm's OLEPTRO antidepressant for MDD

Labopharm Inc. today announced the U.S. Food and Drug Administration (FDA) has approved OLEPTRO(TM) (trazodone hydrochloride) Extended Release Tablets, a novel once-daily formulation of the antidepressant trazodone, for the treatment of major depressive disorder (MDD) in adults. OLEPTRO(TM) utilizes CONTRAMID(R), Labopharm's clinically validated technology that controls the release of active substances within oral medications.

3 Feb 2010

AP offers advice on choosing Medicare Advantage plans

Consumers can switch from original Medicare plans to Medicare Advantage plans until March 31 and to help them understand the options, The Associated Press offers answers to frequent questions about Medicare Advantage plans.

3 Feb 2010

Drug company CEOs under pressure

Dow Jones Newswires/The Wall Street Journal on Severin Schwan, chief executive of Swiss pharmaceutical company Roche Holding AG: "'It is difficult to gauge the impact of the planned U.S. healthcare reform on the pharmaceutical industry,' Schwan told reporters at a media conference to detail 2009 earnings. 'On the one hand, more U.S. citizens will be getting access to healthcare, which is positive. At the same time, pressure on drug prices will certainly increase,' he added." The wire service adds that he also said "decisions on generic biosimilars will be key" (Greil, 2/3).

3 Feb 2010

Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications

Daiichi Sankyo Company, Limited, announced today that it has initiated a new large-scale pivotal Phase III trial for edoxaban, its investigational oral Factor Xa inhibitor. This new study, called HOKUSAI (pronounced hoe·koo·sigh) VTE, is evaluating the safety and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) complications in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE).

3 Feb 2010

The debate over selling insurance across state lines

Kaiser Health News staff writer Phil Galewitz writes that Republicans in Congress have proposed this concept in the past "and Sen. John McCain, R-Ariz., embraced it as part of his 2008 presidential campaign. Advocates - including some insurers and small business groups - say it would give the more than 17 million Americans who buy individual coverage a greater choice of plans and the possibility of lower prices.

3 Feb 2010

BRAF drugs may accelerate tumour growth in cancer patients with faulty RAS gene

A team of UK scientists has made the unexpected discovery that drugs which target a well known fault in a protein called BRAF could actually fuel the progression of cancer in some cases. The findings of this study, which was jointly funded by Cancer Research UK, The Institute of Cancer Research (ICR) and the Wellcome Trust are published in Cell.

3 Feb 2010

First Edition: February 3, 2010

Today's headlines highlight what might be the Democrats' next health reform move in the House, where Speaker Pelosi plans to advance legislation next week to repeal insurance companies' antitrust exemption.

3 Feb 2010

Public policy implications in abstinence-only programs

Study focused on young African American preteens in an urban area: This is a legitimate public health study and it did show that a certain type of abstinence only program can help some very young adolescents (average age 12) delay sexual initiation for up to 24 months.

3 Feb 2010

World Cocoa Foundation launches CLP to improve livelihoods of cocoa farmers in Cote d'Ivoire

At a ceremony held in Abidjan, the World Cocoa Foundation today announced the launch of the Cocoa Livelihoods Program (CLP) in Cote d'Ivoire. The program, first announced in February 2009, funded by the Bill & Melinda Gates Foundation and 14 chocolate industry companies, is expected to significantly improve the livelihoods of 75,000 cocoa farmers in Cote d'Ivoire by 2014.

3 Feb 2010